Literature DB >> 33746883

The Spectrum of PRRT2-Associated Disorders: Update on Clinical Features and Pathophysiology.

Annamaria Landolfi1, Paolo Barone1, Roberto Erro1.   

Abstract

Mutations in the PRRT2 (proline-rich transmembrane protein 2) gene have been identified as the main cause of an expanding spectrum of disorders, including paroxysmal kinesigenic dyskinesia and benign familial infantile epilepsy, which places this gene at the border between epilepsy and movement disorders. The clinical spectrum has largely expanded to include episodic ataxia, hemiplegic migraine, and complex neurodevelopmental disorders in cases with biallelic mutations. Prior to the discovery of PRRT2 as the causative gene for this spectrum of disorders, the sensitivity of paroxysmal kinesigenic dyskinesia to anticonvulsant drugs regulating ion channel function as well as the co-occurrence of epilepsy in some patients or families fostered the hypothesis this could represent a channelopathy. However, recent evidence implicates PRRT2 in synapse functioning, which disproves the "channel hypothesis" (although PRRT2 modulates ion channels at the presynaptic level), and justifies the classification of these conditions as synaptopathies, an emerging rubric of brain disorders. This review aims to provide an update of the clinical and pathophysiologic features of PRRT2-associated disorders.
Copyright © 2021 Landolfi, Barone and Erro.

Entities:  

Keywords:  benign familial infantile seizures; cerebellum; hemiplegic migraine; paroxysmal kinesigenic dyskinesia; synaptic dysfunction

Year:  2021        PMID: 33746883      PMCID: PMC7969989          DOI: 10.3389/fneur.2021.629747

Source DB:  PubMed          Journal:  Front Neurol        ISSN: 1664-2295            Impact factor:   4.003


  1 in total

1.  The Benefit of Multigene Panel Testing for the Diagnosis and Management of the Genetic Epilepsies.

Authors:  Heather Leduc-Pessah; Alexandre White-Brown; Taila Hartley; Daniela Pohl; David A Dyment
Journal:  Genes (Basel)       Date:  2022-05-13       Impact factor: 4.141

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.